Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
AstraZeneca/Merck’s Lynparza Is First Adjuvant Option For BRCA-Positive Breast Cancer
Mar 14 2022
•
By
Joseph Haas
AstraZeneca plants flag with first adjuvant option for BRCA+ breast cancer • Source: Alamy
More from New Products
More from Scrip